Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral Therapy

Phase 3UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cocaine-Related Disorders

Conditions

Cocaine-Related Disorders

Trial Timeline

Oct 1, 2005 → Oct 1, 2012

NCT ID

NCT00249691

About Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral Therapy

Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral Therapy is a phase 3 stage product being developed by Johnson & Johnson for Cocaine-Related Disorders. The current trial status is unknown. This product is registered under clinical trial identifier NCT00249691. Target conditions include Cocaine-Related Disorders.

What happened to similar drugs?

1 of 1 similar drugs in Cocaine-Related Disorders were approved

Approved (1) Terminated (0) Active (0)

✅quetiapineAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00448825	Phase 3	UNKNOWN	Mar 1, 2007	Jun 1, 2013	Alcohol Dependence
NCT00249691	Phase 3	UNKNOWN	Oct 1, 2005	Oct 1, 2012	Cocaine-Related Disorders

Competing Products

3 competing products in Cocaine-Related Disorders

See all competitors

Product	Company	Stage	Hype Score
Topiramate	Johnson & Johnson	Phase 2	35
quetiapine	AstraZeneca	Approved	43
AFQ056 + Placebo	Novartis	Phase 2	35